|
The nexus of intercellular communication is protein and Adnexus plans to capitalize on that. The company makes protein-based drugs called Adnectins, which it believes deliver disease-fighting results superior to antibodies and small molecules. The Adnectins, when combined with the company's PROfusion protein-generation system, combat cancer and musculo-skeletal, neurodegenerative, and autoimmune diseases. The company hopes to avoid patent issues for already existing drugs because Adnectins have a different composition. Adnexus is a subsidiary of Bristol-Myers Squibb.
|
| | | Contact Information | |
Address: |
100 Beaver St.
Waltham, MA 02453
| | Phone: | 781-891-3745 | | Fax: | 781-891-3796 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
President:
John B. Edwards
| | • |
Financial Consultant and Interim Chief Financial Officer:
Lorin J. (Jeff) Randall
| | • |
VP Business Development:
Katrine S. Bosley
|
|
|
